Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896218 | 0.98 | EGFR (0.39) | EGFRDYRK1AAHRTDO2TNF | |
| SCHEMBL11275324 | 0.82 | EGFR (0.36) | EGFRDYRK1AAHRTDO2IKBKB | |
| SCHEMBL30949930 | 0.75 | MAPT (0.40) | EGFRPIK3CA | |
| SCHEMBL28575817 | 0.75 | MAPT (0.40) | EGFRPIK3CA | |
| SCHEMBL23852799 | 0.74 | AHR (0.38) | EGFRDYRK1AAHRTDO2TNF | |
| SCHEMBL3403480 | 0.74 | KDM4A (0.37) | EGFRTDO2 | |
| SCHEMBL7744422 | 0.74 | EGFR (0.36) | EGFRTDO2PIK3CDPIK3CA | |
| SCHEMBL7744423 | 0.74 | AHR (0.35) | AHRTNFRIPK1 | |
| SCHEMBL30917344 | 0.73 | TDO2 (0.39) | EGFRDYRK1AAHRTDO2PIK3CD | |
| SCHEMBL8565229 | 0.73 | AHR (0.37) | EGFRAHRTNFRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 702 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132377-A1 | HEMATOPOIETIC STEM CELL PROLIFERATION MEDIUM AND USE OF THE SAME | FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE (TW) | 2026-05-14 | — | — | US | claimed |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| EP-4692332-A1 | PRODUCTION METHOD FOR MEGAKARYOCYTES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4673532-A1 | THERAPY | Plasticell Limited (GB) | 2026-01-07 | — | — | EP | claimed |
| WO-2025080736-A2 | ORGANOID CULTURE OF BONE MARROW WITH EXPANSION OF CONSTITUENT NORMAL AND MALIGNANT HEMATOPOIETIC CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119677841-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| WO-2025028606-A1 | CULTURE MEDIUM FOR HUMAN CELLS, AND METHOD FOR CULTURING HUMAN HEMATOPOIETIC STEM CELLS | 国立大学法人筑波大学 | 2025-02-06 | — | — | WO | claimed |
| WO-2024210126-A1 | PRODUCTION METHOD FOR MEGAKARYOCYTES | 大塚製薬株式会社 | 2024-10-10 | — | — | WO | claimed |
| US-20240327791-A1 | METHODS OF T CELL PRODUCTION | ADAPTIMMUNE LIMITED (GB) | 2024-10-03 | — | — | US | claimed |
| WO-2024180345-A1 | THERAPY | PLASTICELL LTD (GB) | 2024-09-06 | — | — | WO | claimed |
| US-20180147239-A1 | METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF | HEMA-QUEBEC (CA) | 2018-05-31 | — | — | US | claimed |
| EP-3303570-A1 | METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF | Héma-Québec (CA) | 2018-04-11 | — | — | EP | claimed |
| EP-3247808-A1 | POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY | Fred Hutchinson Cancer Research Center (US) | 2017-11-29 | — | — | EP | claimed |
| WO-2017185179-A1 | METHODS AND COMPOSITIONS FOR EXPANSION OF HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS EMPLOYING A CYTOCHROME P450 1B1 (CYP1B1) INHIBITOR OR A MUSASHI-2 (MSI2) ACTIVATOR | MCMASTER UNIVERSITY (CA) | 2017-11-02 | — | — | WO | claimed |
| WO-2017053729-A1 | NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND ENRICHMENT THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-03-30 | — | — | WO | claimed |
| WO-2016191879-A1 | METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF | Héma-Québec (CA) | 2016-12-08 | — | — | WO | claimed |
| WO-2016118780-A1 | POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2016-07-28 | — | — | WO | claimed |
| WO-2006100479-A1 | METHODS FOR THE SYNTHESIS OF HETEROAROMATIC COMPOUNDS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-09-28 | — | — | WO | claimed |
| EP-0240176-B1 | SUBSTITUTED PYRIMIDOINDOLES | JOHN WYETH & BROTHER LIMITED (GB) | 1990-11-22 | — | — | EP | claimed |
| EP-0240176-A1 | Substituted pyrimidoindoles | JOHN WYETH & BROTHER LIMITED (GB) | 1987-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327791-A1 | METHODS OF T CELL PRODUCTION | ICOS, CD4, PBK | EGFR 4214/4885DYRK1A 3812/4885AHR 218/4885 |
| US-20260132377-A1 | HEMATOPOIETIC STEM CELL PROLIFERATION MEDIUM AND USE OF THE SAME | HGF, IGFBP1, IGF1R | EGFR 296/4885DYRK1A 4034/4885AHR 4/4885 |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | ADAR, RNASE1, CPSF6 | EGFR 3479/4885DYRK1A 2709/4885AHR 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.